IP Library Granted Patent US 10,638,778
Granted Patent B2
US 10,638,778 · App. 16/203,460 · Granted May 5, 2020

Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil

Inventors: Ross M. Franklin (Farmers Branch, TX); Ed Rosenthal (Oakland, CA); Rachel M. Franklin (Farmers Branch, TX)
Assignee: Pivot Pharmaceuticals US Inc.
A23L2/395A21D13/44A21D13/80A23D9/007A23D9/02A23D9/05A23F3/405A23F5/00A23L2/52A23L2/56A23L7/143A23L27/10A23L29/35A23L33/105A61K9/0056A61K9/0095A61K9/146A61K9/20A61K9/48A61K31/352A61K36/185A61K38/02A61K47/36A61K47/38A61K47/44B65D85/808B65D85/8046G01N33/948A23V2002/00A61K2236/37Y02W90/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,638,778
App. No.
16/203,460
Granted
May 5, 2020
Kind
B2
Abstract

A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.

Claims (17)

1. A tablet or capsule consisting essentially of cannabis oil and a mixture of xanthan gum and guar gum.

2. The tablet or capsule of claim 1 , wherein the ratio of the mixture to the cannabis oil, by weight, is at least three grams of the mixture to every one-half of a gram of cannabis oil.

3. The tablet or capsule of claim 1 , wherein the ratio of the mixture to the cannabis oil, by weight, is at least three grams of the mixture to every one-eighth of a gram of cannabis oil.

4. The tablet or capsule of claim 1 , wherein the ratio of the mixture to the cannabis oil, by weight, is at least five grams of the mixture to every one-eighth of a gram of cannabis oil.

5. The tablet or capsule of claim 1 , wherein the ratio of the mixture to the cannabis oil, by weight, is no more than one-eighth of a gram of cannabis oil to every three grams of the mixture.

6. The tablet or capsule of claim 1 , wherein the ratio of the mixture to the cannabis oil, by weight, is between three grams and six grams of the mixture to every one-eighth of a gram of cannabis oil.

7. The tablet or capsule of claim 1 , wherein the cannabis oil is evenly absorbed by the mixture.

8. The tablet or capsule of claim 1 , wherein the cannabis oil contains at least 5 milligrams of tetrahydrocannabinol.

9. The tablet or capsule of claim 1 , wherein the cannabis oil contains between about 5 milligrams and 200 milligrams of tetrahydrocannabinol.

10. The tablet or capsule of claim 1 , wherein the cannabis oil contains 10 milligrams of tetrahydrocannabinol.

11. The tablet or capsule of claim 1 , wherein the cannabis oil contains between about 40 milligrams and 80 milligrams of tetrahydrocannabinol.

12. The tablet or capsule of claim 1 , wherein the cannabis oil has been extracted from cannabis using carbon dioxide extraction.

13. The tablet or capsule of claim 1 , wherein the cannabis oil has been extracted from Cannabis Sativa.

14. The tablet or capsule of claim 1 , wherein the cannabis oil has been extracted from cannabis indica.

15. The tablet or capsule of claim 1 , wherein the cannabis oil is decarboxylated.

16. The tablet or capsule of claim 1 , wherein the cannabis oil is a combination of extracted cannabis oil from two different strains of cannabis.

17. The tablet or capsule of claim 1 , wherein the cannabis oil has been extracted from cannabis using butane extraction.

Assignments (3)
CHANGE OF NAME Recorded Aug 20, 2020
From: PIVOT PHARMACEUTICALS US INC.
To: BETTERLIFE PHARMA US INC.
Reel/Frame 053560/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: PIVOT NATURALS, LLC
To: PIVOT PHARMACEUTICALS US INC.
Reel/Frame 050997/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2019
From: FRANKLIN, ROSS M; ROSENTHAL, ED; FRANKLIN, RACHEL MELISSA
To: PIVOT NATURALS, LLC.
Reel/Frame 047957/0405 →
Continuity (4)
Continuation 15466068 · Mar 22, 2017
Continuation 15049916 · Feb 22, 2016
Provisional Application 62120275 · Feb 24, 2015
Related Publication 20190090512A1 · Mar 28, 2019